| Dec'11 | Dec'10 | Dec'09 | |||
|---|---|---|---|---|---|
Revenue | |||||
19,344 | 9,389 | 623 | |||
Cost of revenue | |||||
28,309 | - | - | |||
Start-up production costs | |||||
- | 19,895 | 5,033 | |||
Research and development | |||||
32,691 | 21,691 | 22,424 | |||
Sales and marketing | |||||
13,600 | 6,111 | 1,798 | |||
General and administrative | |||||
14,039 | 9,345 | 4,953 | |||
Total cost and expenses | |||||
88,639 | 57,042 | 34,208 | |||
Loss from operations | |||||
-69,295 | -47,653 | -33,585 | |||
Interest expense | |||||
2,732 | 2,827 | 3,465 | |||
Interest and other income (expense), net | |||||
-321 | -7,207 | 1,101 | |||
Net loss | |||||
-72,348 | -57,687 | -35,949 | |||
Deemed dividend related to beneficial conversion feature of Series E convertible preferred stock | |||||
- | 405 | - | |||
Net loss attributed to common stockholders | |||||
-72,348 | -58,092 | -35,949 | |||
Net loss per share - basic and diluted | |||||
-2.40 | -13.60 | -386.56 | |||
Weighted-average shares of common stock outstanding used in computing net loss per share attributed to common stockholders-basic and diluted | |||||
30,179 | 4,271 | 92 | |||